GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc (NYSE/LSE: GSK) filed a Form 6-K disclosing the latest execution under its ongoing £5 billion share repurchase programme. On 4 July 2025 the company, via its broker Merrill Lynch International, bought 484,578 ordinary shares (nominal value 31¼ p) on the London Stock Exchange at prices between 1,388.00 p and 1,415.00 p, for a volume-weighted average price of 1,400.75 p. All shares purchased will be held in treasury.
Since the non-discretionary mandate commenced on 4 June 2025 the company has acquired 9,978,493 ordinary shares. After the latest purchase GSK’s treasury stock rises to 228,112,876 shares, representing 5.58 % of total voting rights. The number of shares outstanding (excluding treasury) stands at 4,087,268,974, which is the new denominator for disclosure under the UK FCA’s DTR 5 rules.
No changes to the size or terms of the authorised buy-back were announced; the filing supplies the customary trading-venue and time-stamp breakdown required under UK regulation.
GSK plc filed a Form 6-K disclosing the latest execution under its ongoing share repurchase programme.
- Shares repurchased: 491,972 ordinary shares on 03 July 2025.
- Price range: 1,380.50 p – 1,411.00 p; VWAP: 1,396.15 p.
- Programme history: Since the non-discretionary agreement with Merrill Lynch International on 04 June 2025, the company has bought back 9,493,915 shares.
- Treasury position: After this purchase GSK holds 227,628,298 shares in treasury, equal to 5.57 % of total voting rights.
- Shares outstanding (ex-treasury): 4,087,741,901.
- The repurchase volume on 03 July represents around 0.012 % of shares in issue, while cumulative June–July purchases equal roughly 0.23 %.
The filing provides the standard denominator for Disclosure Guidance and Transparency Rule (DTR) calculations and lists each individual trade executed on the London Stock Exchange. No other financial, operational or strategic information is included.
GSK plc has filed a Form 6-K to report its share capital and voting rights position as of 30 June 2025 under the UK Disclosure Guidance and Transparency Rule 5.6.1R. The company’s issued share capital totals 4,315,370,199 Ordinary Shares of 31 ¼ pence each, of which 226,172,571 shares are held in treasury and therefore do not carry voting rights. After adjusting for these treasury shares, the total number of voting rights currently exercisable amounts to 4,089,197,628. Shareholders should use this denominator when determining whether their holdings cross FCA disclosure thresholds. The notice is signed by Company Secretary Victoria Whyte on 1 July 2025 and provides an email address (company.secretary@gsk.com) for notifications.
GSK has reported a significant share buyback transaction on June 26, 2025. The company purchased 485,032 ordinary shares through Merrill Lynch International at prices ranging from 1,390.00p to 1,405.00p per share, with a volume-weighted average price of 1,397.83p.
Key transaction details:
- All purchases were executed on the London Stock Exchange (XLON)
- Following this purchase, GSK holds 225,206,623 shares in treasury
- Total voting rights now stand at 4,090,138,849
- Treasury shares represent 5.51% of voting rights
This purchase is part of GSK's ongoing buyback programme announced on June 4, 2025, under which the company has acquired 7,072,240 ordinary shares to date. The transaction demonstrates GSK's continued commitment to returning value to shareholders through its share repurchase strategy.
GSK has reported a significant share buyback transaction on June 25, 2025. The company purchased 483,629 ordinary shares at prices ranging from 1,395.00p to 1,411.00p per share, with a volume-weighted average price of 1,400.74p.
Key transaction details:
- All trades were executed on the London Stock Exchange (XLON)
- Following this purchase, GSK holds 224,721,591 shares in treasury
- Total voting rights now stand at 4,090,623,881
- Treasury shares represent 5.49% of voting rights
This purchase is part of GSK's existing buyback program announced on June 4, 2025. Since the program's inception, the company has purchased 6,587,208 ordinary shares, demonstrating significant progress in their capital return strategy.
GSK plc reports a significant share buyback transaction on June 24, 2025. The company purchased 476,537 ordinary shares at prices ranging from 1,403.50p to 1,421.50p per share, with a volume-weighted average price of 1,411.62p.
Key transaction details:
- All trades executed on London Stock Exchange (XLON)
- Part of existing buyback program announced June 4, 2025
- Total shares purchased since program inception: 6,103,579
- Post-transaction treasury holdings: 224,237,962 shares
- Total voting rights: 4,091,107,510
- Treasury shares represent 5.48% of voting rights
The transaction demonstrates GSK's ongoing commitment to returning value to shareholders through its share repurchase program.